Jump to content



Recommended Posts

In reply to: Spicer69 on Wednesday 18/07/07 12:19am

I'm German and excuse for my english. May be it is to strong sometimes. However, it's good for the entertainment in the board IMO! I'm absolutely convinced for SLA an hold many securities many years. Hope the best for next future. http://www.sharescene.com/html/emoticons/smile.gif

Link to comment
Share on other sites

  • Replies 43.2k
  • Created
  • Last Reply

Top Posters In This Topic

  • chiller


  • diana


  • Livas1


  • jezzabot


Top Posters In This Topic

Posted Images

In reply to: Lizard on Wednesday 18/07/07 05:36am

Great article for those yet to discover SLA.


I am guessing it must be more than just approval as they have had many months to draft an announcement up for that.


Maybe a beautiful set of numbers alongside approval for a real share price kicker when the halt is lifted.


Good luck to all holders and those that jump on board.


Best long term growth story on the ASX IMHO of course.

Link to comment
Share on other sites

In reply to: drainer on Wednesday 18/07/07 06:00am





Tiny biotech set to de-liverArticle from: Font size: Decrease Increase Email article: Email Print article: Print John Beveridge


July 18, 2007 12:00am

A SMALL Melbourne biotechnology company has achieved a major breakthrough after getting pharmaceutical registration in Russia.


Solagran will today announce that its drug Ropren can be prescribed for liver disease in Russia.


That means the drug should start to sell in Russia this year, with the next development steps being to seek approval in the rest of Europe and the United States.


Trials have shown Ropren and its active ingredient Bioeffective R is highly effective in treating chronic liver diseases including various forms of hepatitis and cirrhosis.


Further trials both in Russia and Melbourne have also shown Ropren could also be effective in normalising blood lipids such as cholesterol and in treating and preventing neurodegenerative conditions such as Alzheimers and Parkinson's disease.


Solagran shares have been in a trading halt since Monday pending today's announcement.


They have traded from a low of 17 in September last year to a high of $1.55 in May this year.


Solagran has already announced that it is dramatically ramping up European production of Ropren to cater for the estimated 10 million people with liver disease in Russia.


Unlike most drugs, the active ingredient in Ropren is a natural compound known as a polyprenol that is isolated from green conifer needles.


It was first developed in Russia by Professor Victor Roschinback in 1986.


Since Solagran listed in 2003, executive chairman Dr Vagif Soultanov and a Russian project team have successfully pushed to have the drug registered in Russia.


That registration process was shortened significantly because clinical trials showed Ropren to be effective without any of the usual side effects of liver disease drugs.


The Russian Ministry of Health was also keen to introduce a locally discovered drug to combat the high number of liver disease sufferers in the country.


Initially supply of Solagran will be restricted by production, so most treatment courses will be prescribed in Moscow and St Petersburg.


Capacity expansion should see supply grow to the rest of Russia over the next few years.


Given Ropren has pharmaceutical approval in Russia, it may also be used when indicated to treat situations other than its primary role in restoring liver function.


That could include novel applications such as helping to prevent neuronal cell death in the brain following heart attack or stroke and conditions associated with drug and alcohol addiction.



PHONE: 9292 2756

FAX: 9292 1834

EMAIL: beveridgej@heraldsun.com.au


Link to comment
Share on other sites

In reply to: drainer on Wednesday 18/07/07 06:03am

I wonder how he knows this before the ASX release expected or is he taking a stab.


Interesting,all though i suppose it doesnt matter if he got the good oil yesterday and they announce before the market opens this morning.


Will be at work unless it rains so will probably miss the action although the weather is a bit suss at the moment.


Good luck everyone

Link to comment
Share on other sites

In reply to: manoli98 on Wednesday 18/07/07 06:21am

Manoli, that is the understatement of the decade. This is going to revolutionise health prospects for soooooo many people! To be part of such a great discovery and the bringing to market of such a great discovery is unbelievable!!! http://www.sharescene.com/html/emoticons/biggrin.gif




PS: After this, there will be a raft of other releases! http://www.sharescene.com/html/emoticons/graduated.gif

Link to comment
Share on other sites

In reply to: diana on Wednesday 18/07/07 07:48am

Mornin' all


Well the ball has been bounced, let the games begin.


Gentlemen, start your engines!


Exposure in the media beforehand suggests SLA has commenced their PR campaign. A professional leak?


SLA to make ann before 10.00 AM today.


Bring it on. Good luck to all holders and well deserved.


Nifty http://www.sharescene.com/html/emoticons/wub.gif

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...